Clinical laboratory and contract research organization businesses that earn fee-for-service revenue by processing diagnostic tests, specialty / genomic assays, central-lab work, and outsourced clinical-trial services. Revenue is driven by testing volume, reimbursement / price per requisition, specialty mix, trial-service awards, backlog conversion, and working-capital collection efficiency. The te
| Ticker | Company | Their metric | Period | YoY | A year ago |
|---|---|---|---|---|---|
| AMS | American Shared Hospital Services | Proton Beam Radiation Therapy Revenue | FY2026-Q2 | +22.1% | -20.6% |
| MEDP | Medpace Holdings, Inc. | Net New Business Awards Entering Backlog | FY2026-Q1 | +23.7% | -18.8% |
| NEO | NeoGenomics, Inc. | Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization | FY2026-Q2 | +30.8% | -2.3% |
| FLGT | Fulgent Genetics, Inc. | Core Business Revenue Excluding United States Centers for Disease Control and Prevention COVID Next-Generation Sequencing Testing | FY2025-Q2 | +16.4% | +4.8% |
| NEOG | Neogen Corporation | Food Safety | FY2026-Q4 | +3.1% | -3.1% |
| VCYT | Veracyte, Inc. | Testing | FY2026-Q2 | +19.1% | +14.3% |
| GRAL | GRAIL, Inc. | Screening | FY2026-Q2 | +22.6% | +21.8% |
| XGN | Exagen Inc. | Gross Margin (GAAP) | FY2026-Q1 | +0.1 pts | -0.7 pts |
| CSTL | Castle Biosciences, Inc. | DecisionDx-Melanoma Test Reports | FY2026-Q2 | +3.0% | +4.1% |
| MYGN | Myriad Genetics, Inc. | Test Volumes | FY2025-Q4 | +2.1% | +3.9% |
| LH | Labcorp Holdings Inc. | Diagnostics | FY2026-Q2 | +5.5% | +8.9% |
| CDNA | CareDx, Inc | Products | FY2026-Q2 | +8.1% | +11.5% |
| ULS | UL Solutions Inc. | Adjusted Diluted Earnings Per Share | FY2026-Q2 | +13.5% | +18.2% |
| DGX | Quest Diagnostics Incorporated | Diagnostic Information Services | FY2026-Q2 | +10.3% | +15.7% |
| OABI | OmniAb, Inc. | Active Partners | FY2026-Q2 | +10.0% | +20.5% |
| CRL | Charles River Laboratories International, Inc. | Manufacturing Solutions Revenue | FY2026-Q2 | -6.3% | +4.4% |
| FTRE | Fortrea Holdings Inc. | Clinical Services Revenue | FY2026-Q2 | -4.5% | +7.2% |
| GH | Guardant Health, Inc. | Biopharma and Data | FY2026-Q2 | +8.8% | +27.5% |
| OPCH | Option Care Health, Inc. | Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization | FY2026-Q1 | -6.2% | +13.7% |
| ADPT | Adaptive Biotechnologies Corporation | Immune Medicine | FY2026-Q2 | -39.8% | +13.1% |
| PSNL | Personalis, Inc. | Population Sequencing Revenue | FY2026-Q2 | -9.3% | +154.5% |
| ACHV | Achieve Life Sciences, Inc. | ORCA-OL Dosed Participants | FY2026-Q2 | -0.8% | |
| AIDX | Gross Margin | FY2026-Q2 | |||
| BDSX | Biodesix, Inc. | Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization | FY2026-Q2 | ||
| BIAF | bioAffinity Technologies, Inc. | CyPath Lung Sales Volume Growth | FY2026-Q2 | ||
| BLLN | BillionToOne, Inc. | Oncology | FY2026-Q2 | +176.2% | |
| CAI | Caris Life Sciences, Inc. | Clinical Therapy Selection Cases | FY2026-Q1 | ||
| HTFL | Heartflow, Inc. Common Stock | Gross Margin (Non-GAAP) | FY2026-Q1 | ||
| ICCC | ImmuCell Corporation | Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization | FY2026-Q2 | +92.9% | |
| IMDX | Insight Molecular Diagnostics Inc. | Adjusted Loss from Operations | FY2025-Q3 | ||
| IQV | IQVIA Holdings Inc. | Free cash flow | FY2026-Q2 | ||
| LMRI | Lumexa Imaging Holdings, Inc. Common Stock | Consolidated same-center advanced procedure volume growth | FY2026-Q2 | ||
| NRC | National Research Corporation | Total Revenue Projected Under Renewable Contracts | FY2026-Q1 | ||
| NTRA | Natera, Inc. | Tests processed | FY2025-Q3 | +15.2% | |
| QDEL | QuidelOrtho Corporation | Adjusted EBITDA margin | FY2026-Q1 | ||
| RDNT | RadNet, Inc. | Adjusted diluted earnings per share | FY2026-Q1 | -600.0% | |
| SERA | Sera Prognostics, Inc. | States in Active Payer Discussions | FY2026-Q1 | ||
| SHC | Sotera Health Company | Adjusted earnings per share | FY2026-Q2 | ||
| TKNO | Alpha Teknova, Inc. | Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization | FY2024-Q4 | ||
| VNRX | VolitionRx Limited | Walloon Region Non-Dilutive Funding | FY2026-Q1 | -44.4% |
A side-by-side appears only when three or more companies report the same metric under their own definition. Nothing is translated from one company's segment into another's.